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The spike (S) protein of coronaviruses facilitates viral entry into target cells. Entry 68 depends on S protein binding to a cellular receptor and on S protein priming by a cellular 69 protease. SARS-S engages angiotensin-converting enzyme 2 (ACE2) as entry receptor (14) and 70 author/funder. All rights reserved. No reuse allowed without permission.
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S/ACE2 interface has been elucidated and the efficiency of ACE2 usage was found to be a key 72 determinant of SARS-CoV transmissibility (6, 18). SARS-S und 2019-nCoV-S share ~76% 73 amino acid identity. However, it is unknown whether 2019-nCoV-S like SARS-S employs ACE2
74
and TMPRSS2 for host cell entry.
75
Replication-defective vesicular stomatitis virus (VSV) particles bearing coronavirus S 76 proteins faithfully reflect key aspects of coronavirus host cell entry (19). We employed VSV 77 pseudotypes bearing 2019-nCoV-S to study cell entry of 2019-nCoV. Both 2019-nCoV-S and 78 SARS-S were comparably expressed ( Fig. 1A ) and incorporated into VSV particles (Fig. 1B) ,
79
allowing a meaningful side-by-side comparison. We first focused on 2019-nCoV cell tropism.
80
Transduction of cell lines of animal and human origin revealed that all cell lines were readily 81 susceptible to entry driven by the pantropic VSV glycoprotein (VSV-G) (Fig. 1C) , as expected.
82
( Fig. 1C) . Notably, 2019-nCoV-S facilitated entry into an identical spectrum of cell lines as 83 SARS-S (Fig. 1C) , suggesting similarities in receptor choice.
84
Sequence analysis revealed that 2019-nCoV clusters with SARS-CoV-related viruses 85 from bats (SARSr-CoV), of which some but not all can use ACE2 for host cell entry ( Fig (Fig. 3B) . Moreover, directed expression of TMPRSS2 rescued 2019-nCoV-S-driven entry 111 from inhibition by E64d (Fig. 3C ), demonstrating that 2019-nCoV-S uses TMPRSS2 for priming.
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Convalescent SARS patients exhibit a neutralizing antibody response directed against the 113 viral S protein (27). We investigated whether such antibodies block 2019-nCoV-S-driven entry.
114
Serum from a convalescent SARS patient inhibited SARS-S-but not VSV-G-driven entry in a 115 concentration dependent manner (Fig. 4 ). In addition, the serum reduced 2019-nCoV-S-driven 116 entry, although with somewhat lower efficiency as compared to SARS-S (Fig. 4) . Thus, antibody 117 author/funder. All rights reserved. No reuse allowed without permission.
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The finding that 2019-nCoV-S and SARS-S use the same receptor, ACE2, for entry into for ACE2 remains to be compared.
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Priming of coronavirus S proteins by host cell proteases is essential for viral entry into Pseudotyping: VSV pseudotypes were generated according to a published protocol (7).In brief,
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293T transfected to express the viral surface glycoprotein under study were inoculated with a Then, the culture medium was removed and cells were washed once with PBS before 2x SDS-58 sample buffer (0.03 M Tris-HCl, 10% glycerol, 2% SDS, 0.2% bromophenol blue, 1 mM EDTA) 59 was added and cells were incubated for 10 min at room temperature. Next, the samples were 60
